GLP-1 Drugs and Muscle Loss: Clinical Evidence
GLP-1 muscle preservation strategies are essential to prevent lean muscle loss during rapid weight loss from GLP-1 receptor agonists. Adequate protein intake and resistance training help maintain muscle mass. These strategies improve clinical outcomes…
Clinical Evidence and Safety Concerns of Compounded Semaglutide
Compounded semaglutide safety concerns arise due to lack of FDA oversight, leading to variable potency and purity. Clinical evidence shows compounded products differ from FDA-approved semaglutide in quality control. Prescribers must counsel patients on…
Tirzepatide Cardiovascular Mortality Benefit: Evidence & Safety
Tirzepatide cardiovascular mortality benefit is supported by clinical evidence demonstrating a 62% reduction in cardiovascular death risk. This dual receptor agonist offers cardiometabolic protection beyond weight loss. Understanding this benefit helps…